Medical policy: Biofeedback as a Treatment of Headache

Número de política: MP 2.400

Beneficio clínico

  • Minimizar el riesgo o la preocupación de seguridad.
  • Minimizar las intervenciones dañinas o ineficaces.
  • Garantizar el nivel de atención adecuado.
  • Asegurar la duración adecuada del servicio para las intervenciones.
  • Asegurar que se hayan cumplido los requisitos médicos recomendados.
  • Asegurar el lugar apropiado para el tratamiento o servicio.

Fecha de entrada en vigor: 9/1/2026

Política

Biofeedback may be considered medically necessary as part of the overall treatment plan for migraine and tension-type headache.

Biofeedback for the treatment of cluster headache is investigational. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure for the above indications.

Unsupervised home use of biofeedback for treatment of headache is investigational. There is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure for the above indications.

Cross-Reference:

  • MP 1.033 Sacral Nerve Neuromodulation-Stimulation
  • MP 2.029 Neurofeedback
  • MP 2.062 Temporomandibular Disorder
  • MP 2.064 Biofeedback as a Treatment of Chronic Pain
  • MP 2.096 Electromyography (EMG) (Needle and Non-Needle) of the Anal or Urethral Sphincter
  • MP 2.304 Medical Treatments of Autism Spectrum Disorders
  • MP 2.398 Biofeedback as a Treatment of Fecal Incontinence or Constipation
  • MP 2.399 Biofeedback as a Treatment of Urinary Incontinence in Adults
  • MP 2.401 Biofeedback for Miscellaneous Indications
  • MP 4.012 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
  • MP 6.020 Transcutaneous Electrical Nerve Stimulation and Transcutaneous Afferent Patterned Stimulation

Variaciones del producto

Esta política solo se aplica a ciertos programas y productos administrados por Capital Blue Cross y está sujeta a variaciones en los beneficios. Consulte la información adicional a continuación.

FEP PPO - Refer to FEP medical policy manual. The FEP medical policy manual can be found at: fepblue.org/benefit-plans/medical-policies-and-utilization-management-guidelines/medical-policies.

Descripción/Antecedentes

Biofeedback is intended to teach individuals self-regulation of certain physiologic processes not normally considered to be under voluntary control. The various forms of biofeedback mainly differ in the nature of the disease or disorder under treatment, the biologic variable that the subject attempts to control, and the information that is fed back to the subject.

Biofeedback techniques include peripheral skin temperature feedback, blood-volume-pulse feedback (vasoconstriction and dilation), vasoconstriction training (temporalis artery), and electromyographic biofeedback; they may be used alone or in conjunction with other therapies (eg, relaxation, behavioral management, medication). Biofeedback training is done either in individual or group sessions. A typical program consists of 10 to 20 training sessions of 30 minutes each.

Biofeedback has been proposed as a treatment for a variety of diseases and disorders, including anxiety, headaches, hypertension, movement disorders, incontinence, pain, asthma, Raynaud disease, and insomnia.

Headache Overview

Migraine, tension-type, and cluster headache are all primary headaches with distinct presentations. Migraine is characterized by intense, often localized, pain or throbbing usually accompanied by nausea, vomiting, light and/or sound sensitivity. Tension headache pain tends to be less intense and may be bilateral or encircle the head. Both migraine and tension-type headache are relatively common conditions. Cluster headache occurs less frequently. Subjects with cluster headache have brief but intensely painful attacks that occur multiple times per day. Cluster attacks may last days, weeks, or months.

Situación reglamentaria

A variety of biofeedback devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. These devices are designated by the FDA as class II with special controls and are exempt from premarket notification requirements. The FDA defines a biofeedback device as "an instrument that provides a visual or auditory signal corresponding to the status of 1 or more of a patient's physiological parameters (eg, brain alpha wave activity, muscle activity, skin temperature, etc.) so that the patient can control voluntarily these physiological parameters."

Evidence pertaining to the use of biofeedback for urinary incontinence is addressed in evidence review MP 2.399.

Evidence pertaining to the use of biofeedback for chronic pain is addressed in evidence review MP 2.064.

Evidence pertaining to the use of biofeedback for miscellaneous indications (treatment of hypertension, anxiety, asthma, movement disorders [eg, motor function after stroke, injury, or lower-limb surgery], and other applications) is addressed in evidence review MP 2.401.

Evidence pertaining to the use of biofeedback for fecal incontinence or constipation is addressed in evidence review MP 2.398.

Fundamento

For individuals who have migraines or tension-type headaches who receive biofeedback, the evidence includes systematic reviews. Los resultados relevantes incluyen síntomas, resultados funcionales y calidad de vida. The literature, which includes meta-analyses of a large number of controlled and uncontrolled studies, has suggested that this treatment can reduce the frequency and/or severity of migraines and tension-type headaches. Biofeedback, along with other psychologic and behavioral techniques (eg, relaxation training) may be particularly useful for children, pregnant women, and other adults who are unable to take certain medications. Las pruebas son suficientes para determinar que la tecnología da lugar a una mejora en el resultado neto para la salud.

For individuals who have cluster headache who receive biofeedback, the evidence includes small case series and case reports. Los resultados relevantes incluyen síntomas, resultados funcionales y calidad de vida. No controlled trials were identified on biofeedback for cluster headache. Las pruebas son insuficientes para determinar que la tecnología da lugar a una mejora en el resultado neto para la salud.

Definiciones

Electromyogram (EMG): is the graphic record of resting and voluntary muscle activities as a result of electrical stimulation.

Physiologic: pertains to normal functions of the human body as opposed to pathological.

Exención de responsabilidad

Las políticas médicas de Capital Blue Cross se utilizan para determinar la cobertura de tecnologías, procedimientos, equipos y servicios médicos específicos. Estas políticas médicas no constituyen asesoramiento médico y están sujetas a cambios según lo exija la ley o las pruebas clínicas aplicables de las directrices de tratamiento independientes. Los proveedores que brindan tratamiento son individualmente responsables de los consejos médicos y el tratamiento de los miembros. Estas políticas no son una garantía de cobertura o pago. El pago de las reclamaciones está sujeto a la determinación del programa de beneficios del miembro y la elegibilidad en la fecha del servicio, y a la determinación de que los servicios son médicamente necesarios y apropiados. El procesamiento final de una reclamación se basa en los términos del contrato que se aplican al programa de beneficios de los miembros, incluidas las limitaciones y exclusiones de beneficios. Si un proveedor o miembro tiene alguna pregunta sobre esta política médica, debe comunicarse con Servicios para proveedores o Servicios para miembros de Capital Blue Cross.

Información de codificación

Nota: esta lista de códigos puede no ser exhaustiva y los códigos están sujetos a cambios en cualquier momento. La identificación de un código en esta sección no denota cobertura, ya que la cobertura está determinada por los términos de la información de beneficios del miembro. Además, no todos los servicios cubiertos son elegibles para un reembolso por separado.

Cubierto cuando es médicamente necesario

Códigos de procedimiento

90875*

90876*

90901

 

 

*covered when BOTH psychotherapy & biofeedback are provided

Bajo investigación; por lo tanto, no se cubre:

Códigos de procedimiento

E0746

 

 

 

 

Códigos de diagnóstico ICD-10-CM
Descripción

G43.001

Migraine without aura, not intractable, with status migrainosus

G43.009

Migraine without aura, not intractable, without status migrainosus

G43.011

Migraine without aura, intractable, with status migrainosus

G43.019

Migraine without aura, intractable, without status migrainosus

G43.101

Migraine with aura, not intractable, with status migrainosus

G43.109

Migraine with aura, not intractable, without status migrainosus

G43.111

Migraine with aura, intractable, with status migrainosus

G43.119

Migraine with aura, intractable, without status migrainosus

G43.401

Hemiplegic migraine, not intractable, with status migrainosus

G43.409

Hemiplegic migraine, not intractable, without status migrainosus

G43.411

Hemiplegic migraine, intractable, with status migrainosus

G43.419

Hemiplegic migraine, intractable, without status migrainosus

G43.501

Persistent migraine aura without cerebral infarction, not intractable, with status migrainosus

G43.509

Persistent migraine aura without cerebral infarction, not intractable, without status migrainosus

G43.511

Persistent migraine aura without cerebral infarction, intractable, with status migrainosus

G43.519

Persistent migraine aura without cerebral infarction, intractable, without status migrainosus

G43.601

Persistent migraine aura with cerebral infarction, not intractable, with status migrainosus

G43.609

Persistent migraine aura with cerebral infarction, not intractable, without status migrainosus

G43.611

Persistent migraine aura with cerebral infarction, intractable, with status migrainosus

G43.619

Persistent migraine aura with cerebral infarction, intractable, without status migrainosus

G43.701

Chronic migraine without aura, not intractable, with status migrainosus

G43.709

Chronic migraine without aura, not intractable, without status migrainosus

G43.711

Chronic migraine without aura, intractable, with status migrainosus

G43.719

Chronic migraine without aura, intractable, without status migrainosus

G43.801

Other migraine, not intractable, with status migrainosus

G43.809

Other migraine, not intractable, without status migrainosus

G43.811

Other migraine, intractable, with status migrainosus

G43.819

Other migraine, intractable, without status migrainosus

G43.821

Menstrual migraine, not intractable, with status migrainosus

G43.829

Menstrual migraine, not intractable, without status migrainosus

G43.831

Menstrual migraine, intractable, with status migrainosus

G43.839

Menstrual migraine, intractable, without status migrainosus

G43.901

Migraine, unspecified, not intractable, with status migrainosus

G43.909

Migraine, unspecified, not intractable, without status migrainosus

G43.911

Migraine, unspecified, intractable, with status migrainosus

G43.919

Migraine, unspecified, intractable, without status migrainosus

G43.B0

Ophthalmoplegic migraine, not intractable

G43.B1

Ophthalmoplegic migraine, intractable

G43.C0

Periodic headache syndromes in child or adult, not intractable

G43.C1

Periodic headache syndromes in child or adult, intractable

G43.E01

Chronic migraine with aura, not intractable, with status migrainosus

G43.E09

Chronic migraine with aura, not intractable, without status migrainosus

G43.E11

Chronic migraine with aura, intractable, with status migrainosus

G43.E19

Chronic migraine with aura, intractable, without status migrainosus

G44.201

Tension-type headache, unspecified, intractable

G44.209

Tension-type headache, unspecified, not intractable

G44.211

Episodic tension-type headache, intractable

G44.219

Episodic tension-type headache, not intractable

G44.221

Chronic tension-type headache, intractable

G44.229

Chronic tension-type headache, not intractable

Referencias

  1. Baraness L, Baker AM. Acute Headache. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Updated July 26, 2023. Último acceso el 24 de septiembre de 2025.
  2. Food and Drug Administration. Biofeedback device. 21 CFR - 882.5050 (1998). Último acceso el 22 de septiembre de 2025.
  3. Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. Jul 2021; 61(7): 1021-1039. PMID 34160823
  4. Paudel P, Sah A. Efficacy of biofeedback for migraine: A systematic review and meta-analysis. Complement Ther Med. Jun 2025; 90: 103153. PMID 40064357
  5. Nestoriuc Y, Martin A. Efficacy of biofeedback for migraine: a meta-analysis. Pain. Mar 2007; 128(1-2): 111-27. PMID 17084028
  6. Nestoriuc Y, Rief W, Martin A. Meta-analysis of biofeedback for tension-type headache: efficacy, specificity, and treatment moderators. J Consult Clin Psychol. Junio de 2008; 76(3): 379-96. PMID 18540732
  7. Verhagen AP, Damen L, Berger MY, et al. Behavioral treatments of chronic tension-type headache in adults: are they beneficial?. CNS Neurosci Ther. 2009; 15(2): 183-205. PMID 19499626
  8. Martino Cinnera A, Morone G, Bisirri A, et al. Headaches treatment with EMG biofeedback: a focused systematic review and meta-analysis. Eur J Phys Rehabil Med. Dec 2023; 59(6): 697-705. PMID 37823248
  9. Arce Seaz D, Berring-Uldum AA, Deles NMM. Nonpharmacologic Treatment Options in Pediatric Tension-Type Headache Patients: A Systematic Review. J Child Neurol. Nov 2024; 39(13-14): 510-520. PMID 39252526
  10. Stubberud A, Varkey E, McCrory DC, et al. Biofeedback as Prophylaxis for Pediatric Migraine: A Meta-analysis. Pediatrics. Aug 2016; 138(2). PMID 27462067
  11. Association for Applied Psychophysiology and Biofeedback. Standards for Performing Biofeedback. 2013; Accessed September 24, 2025.
  12. VA/DoD Clinical Practice Guideline. (2023). Management of Headache Work Group. Washington, DC: U.S. Government Printing Office. Último acceso el 24 de septiembre de 2025.
  13. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Biofeedback Therapy (30.1). n.d; Accessed September 24, 2025.

Antecedentes de la política

MP 2.400

12/18/2025 Major Review. Biofeedback as a treatment of headache taken from MP 2.064 and placed into this new policy. Policy stance language updated. Policy cross-references, background, rationale, coding, and references updated.